Titre:
  • Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Auteur:Delforge, Michel; Selleslag, Dominik; Beguin, Yves; Triffet, Agnès; Mineur, Philippe; Theunissen, Koen; Graux, Carlos; André, Marc; Trullemans, Fabienne; Boulet, Dominique; Van Eygen, Koen; Noens, Lucien; Van Steenweghen, Steven; Lemmens, Jan; Pierre, Pascal; D'hondt, Randal; Ferrant, Augustin; Deeren, Dries; Van de Velde, Ann; Wynendaele, Wim; De Bock, Robrecht; Efira, André; Breems, Dimitri D.A.; Deweweire, Anne; Geldhof, Kurt; Pluymers, Wim; Harrington, Amanda; MacDonald, Karen; Abraham, Ivo; Ravoet, Christophe
Informations sur la publication:Leukemia research, 38, 5, page (557-563)
Statut de publication:Publié, 2014
Sujet CREF:Cancérologie
Hématologie
Mots-clés:Cardiac death
Chelation therapy
Iron overload
Myelodysplastic syndromes
Transfusion
Transfusion dependency
MeSH keywords:Aged
Blood Transfusion
Female
Humans
Iron Chelating Agents -- therapeutic use
Male
Middle Aged
Myelodysplastic Syndromes -- drug therapy -- mortality
Retrospective Studies
Risk
Time Factors
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0145-2126
info:doi/10.1016/j.leukres.2014.02.003
info:pii/S014521261400037X
info:scp/84899082162
info:pmid/24661630